Latest & greatest articles for nivolumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on nivolumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on nivolumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for nivolumab

81. Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V

Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Plattenepithelkarzinom des Kopf-Hals- Bereichs) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 August 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally (...) binding. IQWiG Reports – Commission No. A17-24 Nivolumab (squamous cell carcinoma of the head and neck) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-24 Version 1.0 Nivolumab (squamous cell carcinoma of the head and neck) 30 August 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (squamous cell carcinoma of the head and neck) – Benefit

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

82. Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision) Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Nivolumab (Melanom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 13 September 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-27 (...) Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V 1 (expiry of the decision) Extract of dossier assessment A17-27 Version 1.0 Nivolumab (melanoma) 13 September 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (melanoma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 June

2017 Institute for Quality and Efficiency in Healthcare (IQWiG)

83. Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)

Nivolumab (Opdivo©) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Grössmann N Record Status This is a bibliographic record of a published health (...) technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions The treatment of nivolumab offers durable responses, 31.1% demonstrated

2017 Health Technology Assessment (HTA) Database.

84. Nivolumab for the treatment of renal-cell carcinoma

Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Nivolumab for the treatment of renal-cell carcinoma Soto N, López A, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Soto N, López A, Pichon (...) -Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, Rey-Ares L. Nivolumab for the treatment of renal-cell carcinoma. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rapida No. 491. 2016 Authors' conclusions No evidence has been identified on the use of nivolumab as first-line treatment or in localized renal-cell carcinoma stage. High-quality evidence, coming from a single study in patients with clear cell histology, indicates

2016 Health Technology Assessment (HTA) Database.

85. Nivolumab for previously treated advanced renal cell carcinoma

Nivolumab for previously treated advanced renal cell carcinoma Niv Nivolumab for pre olumab for previously treated viously treated advanced renal cell carcinoma advanced renal cell carcinoma T echnology appraisal guidance Published: 23 November 2016 nice.org.uk/guidance/ta417 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for previously treated advanced renal cell carcinoma (TA417) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents 1 Recommendations 4 2 The technology 5 3

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

86. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Institut für Qualität und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nierenzellkarzinom): nutzenbewertung gemäß § 35a SGB V; auftrag A16-24. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a Social Code Book V; assignment A16-24] Cologne

2016 Health Technology Assessment (HTA) Database.

87. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25 [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Institut für Qualität und Wirtschaftlichkeit im (...) Gesundheitswesen (IQWiG) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (nicht plattenepitheliales NSCLC): nutzenbewertung gemäß § 35a SGB V; auftrag A16-25. [Nivolumab (new therapeutic indication) – benefit assessment according to §35a SGB V; assignment A16-25] Cologne

2016 Health Technology Assessment (HTA) Database.

88. Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma - first line

Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma - first line Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation NIHR HSRIC. Nivolumab (Opdivo) and ipilimumab (Yervoy) for advanced or metastatic renal cell carcinoma – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Nivolumab and ipilimumab are two drugs used to treat renal cell carcinoma, which is the most common form of kidney cancer. Many people with kidney cancer show no symptoms for many years and are often diagnosed late, after the cancer has spread. Nivolumab

2016 Health Technology Assessment (HTA) Database.

89. [Nivolumab (new therapeutic indication)]

[Nivolumab (new therapeutic indication)] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35 [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35 [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) Record (...) Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Nivolumab (melanom): nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A16-35. [Nivolumab (new therapeutic indication) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und

2016 Health Technology Assessment (HTA) Database.

90. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared (...) status of 0 or 1. Patients were randomly assigned 2:1 to receive an intravenous infusion of nivolumab 1 mg/kg plus ipilimumab 3 mg/kg or ipilimumab 3 mg/kg plus placebo, every 3 weeks for four doses. Subsequently, patients assigned to nivolumab plus ipilimumab received nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity, whereas patients allocated to ipilimumab alone received placebo every 2 weeks during this phase. Randomisation was done via an interactive voice

Full Text available with Trip Pro

2016 EvidenceUpdates

91. Nivolumab - Addendum to Commission A15-27

Nivolumab - Addendum to Commission A15-27 1 Translation of addendum A15-50 Nivolumab (Addendum zum Auftrag A15-27) (Version 1.0; Status: 11 December 2015). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 11 December 2015 1.0 Commission: A15-50 Version: Status: IQWiG Reports – Commission No. A15-50 Nivolumab (Addendum to Commission A15-27) 1 Addendum A15 (...) -50 Version 1.0 Nivolumab (Addendum to Commission A15-27) 11 December 2015 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab (Addendum to Commission A15-27) Commissioning agency: Federal Joint Committee Commission awarded on: 24 November 2015 and 1 December 2015 Internal Commission No.: A15-50 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

92. Nivolumab - Addendum to Commission A15-32

Nivolumab - Addendum to Commission A15-32 1 Translation of addendum A15-58 Nivolumab – Addendum zum Auftrag A15-32 (Version 1.0; Status: 13 January 2016). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 13 January 2016 1.0 Commission: A15-58 Version: Status: IQWiG Reports – Commission No. A15-58 Nivolumab – Addendum to Commission A15-32 1 Addendum A15 (...) -58 Version 1.0 Nivolumab – Addendum to Commission A15-32 13 January 2016 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Nivolumab – Addendum to Commission A15-32 Commissioning agency: Federal Joint Committee Commission awarded on: 22 December 2015 Internal Commission No.: A15-58 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln

2016 Institute for Quality and Efficiency in Healthcare (IQWiG)

93. Nivolumab in combination with ipilimumab for treating advanced melanoma

Nivolumab in combination with ipilimumab for treating advanced melanoma Niv Nivolumab in combination with olumab in combination with ipilimumab for treating advanced ipilimumab for treating advanced melanoma melanoma T echnology appraisal guidance Published: 27 July 2016 nice.org.uk/guidance/ta400 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 25Contents Contents 1

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

94. Nivolumab (Opdivo) for treatment of non-small cell lung cancer

Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer Nivolumab (Opdivo) for treatment of non-small cell lung cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nivolumab (Opdivo) for treatment of non-small cell lung cancer. Lansdale: HAYES, Inc.. Healthcare (...) Technology Brief Publication. 2016 Authors' conclusions Description of Technology: Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to programmed death (PD-1) pathway that is active in non-small cell lung cancer (NSCLC). Nivolumab inhibits PD-1, preventing it from interacting with its ligands and permitting activated T cells to attack tumor cells. Patient Population: Nivolumab is indicated for the treatment of metastatic NSCLC in patients with progression on or after platinum-based

2016 Health Technology Assessment (HTA) Database.

95. [Nivolumab - addendum to commission A15-32]

[Nivolumab - addendum to commission A15-32] Nivolumab: addendum zum auftrag A15-32; auftrag A15-58 [Nivolumab - addendum to commission A15-32] Nivolumab: addendum zum auftrag A15-32; auftrag A15-58 [Nivolumab - addendum to commission A15-32] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Nivolumab: addendum zum auftrag A15-32; auftrag A15-58. [Nivolumab - addendum to commission A15-32] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 356. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Programmed Cell Death 1 Receptor Language Published German Country of organisation Germany English

2016 Health Technology Assessment (HTA) Database.

96. Nivolumab for follicular non-Hodgkin lymphoma Ä third line

Nivolumab for follicular non-Hodgkin lymphoma Ä third line Nivolumab for follicular non-Hodgkin lymphoma ─ third line Nivolumab for follicular non-Hodgkin lymphoma ─ third line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab for follicular non-Hodgkin lymphoma ─ third line. Birmingham: NIHR Horizon Scanning Research&Intelligence (...) Centre. Horizon Scanning Review. 2016 Authors' objectives Lymphoma is a cancer of the lymphatic system, which is part of the immune system. It contains cells called lymphocytes that fight infections. Follicular lymphoma is the second most common type of non-Hodgkin lymphoma. It often progresses slowly, with patients showing no symptoms for many years. Nivolumab is a new antibody drug for the treatment of follicular lymphoma that is delivered straight into the bloodstream via a drip. Some studies have

2016 Health Technology Assessment (HTA) Database.

97. Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer - first line

Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer - first line Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR (...) HSRIC. Nivolumab (Opdivo) for stage IV or recurrent PD-L1 positive non-small cell lung cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Nivolumab is a new drug for the treatment of a specific type of non-small cell lung cancer. It is given as a drip

2016 Health Technology Assessment (HTA) Database.

98. Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer - first line

Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer - first line Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer – first line Nivolumab (Opdivo) for stage IV or recurrent non-small cell lung cancer – first line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for stage IV (...) or recurrent non-small cell lung cancer – first line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Non-small cell lung cancer is the most common type of lung cancer. It is often diagnosed late and is difficult to treat once it has spread to other parts of the body. Nivolumab is a new drug for the treatment of non-small cell lung cancer. It is given as a drip into a vein once every two weeks. Some studies have suggested nivolumab may

2016 Health Technology Assessment (HTA) Database.

99. Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer - second line

Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer - second line Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer – second line Nivolumab (Opdivo) for metastatic or unresectable urothelial bladder cancer – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo (...) will be diagnosed with disease that has spread outside of the bladder. Nivolumab is a new antibody drug for the treatment of bladder cancer and is delivered straight into the bloodstream via a drip. It may stimulate the immune system to attack cancer cells. A study underway at the moment is aiming to find out how well nivolumab works in people whose first treatment has failed and whose disease has spread. If nivolumab is licenced for use in the UK, it could be a new treatment option for patients with bladder

2016 Health Technology Assessment (HTA) Database.

100. Nivolumab for treating advanced (unresectable or metastatic) melanoma

Nivolumab for treating advanced (unresectable or metastatic) melanoma Niv Nivolumab for treating advanced olumab for treating advanced (unresectable or metastatic) melanoma (unresectable or metastatic) melanoma T echnology appraisal guidance Published: 18 February 2016 nice.org.uk/guidance/ta384 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 36Contents Contents 1

2016 National Institute for Health and Clinical Excellence - Technology Appraisals